Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001

Thierry Facon, Sagar Lonial, MD, Brendan M Weiss, MD, Attaya Suvannasankha, MD, Joseph Fay, Bertrand Arnulf, Jainulabdeen J Ifthikharuddin, Carla de Boer, Jianping Wang, Kaida Wu, Ajai Chari, Suzanne Lentzsch, Jordan Schecter, Amrita Krishnan, MD

Blood (2017) 130 (Supplement 1): 1824.

https://doi.org/10.1182/blood.V130.Suppl_1.1824.1824

Published: 2017

Journal Articles

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Ajai Chari, Attaya Suvannasankha, Joseph W. Fay, Bertrand Arnulf, Jonathan L. Kaufman, Jainulabdeen J. Ifthikharuddin, Brendan M. Weiss, Amrita Krishnan, Suzanne Lentzsch, Raymond Comenzo, Jianping Wang, Kerri Nottage, Christopher Chiu, Nushmia Z. Khokhar, Tahamtan Ahmadi, Sagar Lonial

Blood (2017) 130 (8): 974–981.

https://doi.org/10.1182/blood-2017-05-785246

Published: 2017

Includes: Supplemental data

Journal Articles

Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma

Ajai Chari, MD, Sagar Lonial, MD, Attaya Suvannasankha, Joseph W. Fay, Bertrand Arnulf, Jainulabdeen J. Ifthikharuddin, Xiang Qin, Tara Masterson, Kerri Nottage, Jordan M Schecter, Tahamtan Ahmadi, Brendan Weiss, Amrita Krishnan, Suzanne Lentzsch

Blood (2015) 126 (23): 508.

https://doi.org/10.1182/blood.V126.23.508.508

Published: 2015

Journal Articles

Randomized Comparison of Melphalan 200 Mg/m 2 v. 280 Mg/m 2 As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

William I. Bensinger, MD, Pamela S Becker, MD, PhD, Ted A. Gooley, PhD, Thomas Chauncey, MD, PhD, David G. Maloney, MD, PhD, Robert Vescio, MD, Ajay K. Gopal, MD, Damian J. Green, MD, Oliver W. Press, MD, PhD, Michael Lill, M.D., Leona Holmberg, MD, PhD, Jainulabdeen J Ifthikharuddin, MD, Gordon L. Phillips, II, MD

Blood (2012) 120 (21): 2009.

https://doi.org/10.1182/blood.V120.21.2009.2009

Published: 2012

Journal Articles

Geographic and Racial Disparities In Multiple Myeloma Outcomes In the USA

Shahrukh Hashmi, MD, MPH, Chris Mooney, MA, MPH, Gordon L. II Phillips, MD, Jane L. Liesveld, MD, Jainulabdeen J Ifthikharuddin, MD

Blood (2010) 116 (21): 2557.

https://doi.org/10.1182/blood.V116.21.2557.2557

Published: 2010

Journal Articles

Salvage Autologous Hematpoeitic Stem Cell Transplants (AHSCT2) for Myeloma: Single Center Experience.

Bishoy Faltas, MD, Jane L. Liesveld, MD, Michael Becker, Jainulabdeen J. Ifthikharuddin, MD, Gordon L. Phillips, II, MD

Blood (2010) 116 (21): 4591.

https://doi.org/10.1182/blood.V116.21.4591.4591

Published: 2010

Journal Articles

Phase I Study of Cladribine, Cytarabine (Ara-C), Granulocyte Colony Stimulating Factor (G-CSF) (CLAG Regimen) and Simultaneous Escalating Doses of Imatinib Mesylate (Gleevec) in Relapsed/Refractory AML.

Camille N. Abboud, MD, Alison Walker, MD, Rami S. Komrokji, MD, Jainulabdeen J. Ifthikharuddin, MD, Connie Sparks, BS,CRA, Kelly Likly, MSN, Patti Messina, BSN, Deborah Mulford, MD, Jonathan Friedberg, MD, Michael W. Becker, MD, Faith Young, MD, Steven H. Bernstein, MD, August J. Salvado, MD, Gordon L. Phillips, MD, Jane L. Liesveld, MD

Blood (2006) 108 (11): 1958.

https://doi.org/10.1182/blood.V108.11.1958.1958

Published: 2006

Journal Articles

Phase I Study for Poor Prognosis Lymphoma: Modification of the “BEAM” (BCNU +Etoposide+ARA-C+Melphalan) Regimen with Escalating-Dose Melphalan (MEL) Using Amifostine (AF) Cytoprotection and Autologous Hematopoietic Stem Cell Transplantation (AHSCT).

Gordon L. Phillips, MD, Camille N. Abboud, MD, Steven H. Bernstein, MD, Jonathan W. Friedberg, MD, Michael W. Becker, MD, Jainulabdeen J. Ifthikharuddin, MD, Faith Young, MD, Jane L. Liesveld, MD

Blood (2006) 108 (11): 3076.

https://doi.org/10.1182/blood.V108.11.3076.3076

Published: 2006

Journal Articles

High Incidence of Thromboembolic Complications and PF4 Positivity in Patients with Ventricular Assist Devices.

Brandon J. McMahon, MD, Jainulabdeen J. Ifthikharuddin, MD, Elie Dib, MD, Leway Chen, MD, Charles W. Francis, MD, Todd H. Massey, MD

Blood (2006) 108 (11): 4083.

https://doi.org/10.1182/blood.V108.11.4083.4083

Published: 2006

Journal Articles

Improved Methodology for Detection of Mutations in the BCR-ABL Fusion Gene That Cause Resistance to the Tyrosine Kinase Inhibitor Imatinib.

Paul G. Rothberg, PhD, Roberto L. Vargas, MD, Jane L. Liesveld, MD, Jainulabdeen J. Ifthikharuddin, MD, Sharon D. Frazier, BS, Susan L. Polochock, AAS

Blood (2006) 108 (11): 2341.

https://doi.org/10.1182/blood.V108.11.2341.2341

Published: 2006

Journal Articles

Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin

Martin S. Zand, Thuong Vo, Tina Pellegrin, Raymond Felgar, Jane L. Liesveld, Jainulabdeen J. Ifthikharuddin, Camille N. Abboud, Ignacio Sanz, Jennifer Huggins

Blood (2006) 107 (7): 2895–2903.

https://doi.org/10.1182/blood-2005-06-2269

Published: 2006

Journal Articles

Extracorporeal Photopheresis, Pentostatin, and TBI for Reduced-Intensity Preparation: Adaptation of the Tufts Experience at a Single Transplant Center.

Jane L. Liesveld, MD, Camille N. Abboud, MD, Stephen H. Bernstein, MD, Jonathan Friedberg, MD, Jainulabdeen J. Ifthikharuddin, MD, Louis S. Constine, MD, Karen L. Kaplan, MD, PhD, Lucy A. Wedow N.P., Diane D. Nichols, BS, Jamie Oliva, N.P., Maryanne Etter, N.P, Gordon L. Phillips, MD

Blood (2005) 106 (11): 5417.

https://doi.org/10.1182/blood.V106.11.5417.5417

Published: 2005

NARROW

Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma

Randomized Comparison of Melphalan 200 Mg/m 2 v. 280 Mg/m 2 As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Geographic and Racial Disparities In Multiple Myeloma Outcomes In the USA

Salvage Autologous Hematpoeitic Stem Cell Transplants (AHSCT2) for Myeloma: Single Center Experience.

Phase I Study of Cladribine, Cytarabine (Ara-C), Granulocyte Colony Stimulating Factor (G-CSF) (CLAG Regimen) and Simultaneous Escalating Doses of Imatinib Mesylate (Gleevec) in Relapsed/Refractory AML.

Phase I Study for Poor Prognosis Lymphoma: Modification of the “BEAM” (BCNU +Etoposide+ARA-C+Melphalan) Regimen with Escalating-Dose Melphalan (MEL) Using Amifostine (AF) Cytoprotection and Autologous Hematopoietic Stem Cell Transplantation (AHSCT).

High Incidence of Thromboembolic Complications and PF4 Positivity in Patients with Ventricular Assist Devices.

Improved Methodology for Detection of Mutations in the BCR-ABL Fusion Gene That Cause Resistance to the Tyrosine Kinase Inhibitor Imatinib.

Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin

Extracorporeal Photopheresis, Pentostatin, and TBI for Reduced-Intensity Preparation: Adaptation of the Tufts Experience at a Single Transplant Center.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only